Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8191631 | 0.79 | MMP9 (0.55) | CHRM5CHRM1MMP9MMP1MMP2 | |
| SCHEMBL14553734 | 0.77 | ALDH1A1 (0.51) | MMP9MMP1MMP2MMP12ALDH1A1 | |
| SCHEMBL16689961 | 0.75 | KMT2A (0.67) | MMP9MMP1MMP2MMP12ALDH1A1 | |
| SCHEMBL19775347 | 0.74 | TDP1 (0.56) | CHRM5CHRM1MMP9MMP1MMP2 | |
| SCHEMBL1144592 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPTNPC1POLBRAB9A | |
| SCHEMBL155140 | 0.73 | ALDH1A1 (0.57) | MMP9MMP1MMP2MMP12ALDH1A1 | |
| SCHEMBL29024631 | 0.72 | RAB9A (0.63) | MMP9MMP1MMP2MMP12ALDH1A1 | |
| SCHEMBL3758807 | 0.72 | ALDH1A1 (0.60) | MMP9MMP1MMP2MMP12ALDH1A1 | |
| SCHEMBL292834 | 0.72 | ALDH1A1 (0.60) | MMP9MMP1MMP2MMP12ALDH1A1 | |
| SCHEMBL28049332 | 0.72 | SLC6A4 (0.53) | MMP9MMP1MMP2MMP12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | CHRM5 366/4885CHRM1 280/4885MMP9 3375/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | CHRM5 391/4885CHRM1 274/4885MMP9 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.